Intraductal papilloma (IP) constitutes a rare benign neoplasm among male population with only few reports on childhood patients. Herein, we describe an 11-year-old IP male patient who presented with spontaneous nipple discharge of his right breast.
View Article and Find Full Text PDFIntroduction: The aim of this observational study was to assess the combined impact of chemotherapy (CT) and aromatase inhibitors (AI) therapy on bone mineral density (BMD) in postmenopausal women with estrogen receptor (ER)-positive early breast cancer.
Methods: Patients were treated with a third generation AI, either as adjuvant therapy (HT cohort, n = 166) or as subsequent endocrine therapy after initial treatment with chemotherapy (CT cohort, n = 124), and were followed up for a 12-month period. BMD was evaluated at lumbar spine (LS) and total hip (HP) before CT, before AI therapy and after 12 months of AI therapy.
Purpose: HER2 gene amplification and overexpression is associated with aggressive breast cancer and poor prognosis. Accurate HER2 testing of patients with breast cancer before treatment is important to ensure that as many patients with HER2-positive breast cancer as possible receive the most appropriate treatment and that women with HER2-negative disease avoid a potentially toxic therapy. This study compares immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) HER2 testing at central and regional laboratories in Greece.
View Article and Find Full Text PDFRecently, using an ultrasensitive time-resolved immuno-fluorometric assay, PSA immunoreactivity (IR-PSA) was found in breast tumor cytosols. We retrospectively studied 219 breast cancer patients, measuring IR-PSA in the tumor cytosols, and classified the breast cancers as either PSA positive or PSA negative based on an IR-PSA cut off level of 1 pg/mg. Multivariated analysis showed that IR-PSA is an independent favourable prognostic indicator for postmenopausal, node positive breast cancer patients.
View Article and Find Full Text PDF